D009292Chemicals & DrugsD27.505.696.543D27.505.696.663.850.512D27.505.954.427.5509140.993084Narcotic AntagonistsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.2901190.01024429research area of0.7498470.04126212subject area fortrue1ProfessorProfessorAnesthesiologyPsychiatrytrue1ProfessorProfessorAsokumarBuvanendranAsokumar Buvanendran349536Buvanendran, AsokumarProfessorKathleenWeberKathleen Weber349609Weber, KathleenAssistant ProfessorJohnZajeckaJohn Zajecka349738Zajecka, JohnProfessor6Assistant Professor4Professor23512167Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD, Hegde SS, Beattie DTNaunyn-Schmiedeberg's archives of pharmacologyThe in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun; 386(6):471-8.Naunyn Schmiedebergs Arch Pharmacol2013-03-13T00:00:002013The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.33125454Fava M, Mazzone E, Freeman M, Flynn M, Judge H, Hoeppner B, Hock RS, Shui A, Macaluso M, Morrison MF, Carpenter LL, Shelton R, Zajecka J, Papakostas GIAnnals of clinical psychiatry : official journal of the American Academy of Clinical PsychiatristsDouble-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2020 02; 32(4):18-26.Ann Clin Psychiatry2020-02-01T00:00:002020Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.Internal MedicineBehavioral SciencesRush University, Rush Medical CollegeJohnBurnsJohn Burns41.87328300000000-87.66936330000000349016Burns, JohnProfessortrue1Assistant ProfessorAssistant ProfessorInternal Medicine, Division of Digestive Diseases and NutritionAjaypalSinghAjaypal Singh349809Singh, AjaypalAssistant Professortrue1ProfessorProfessor28365372Burns JW, Bruehl S, France CR, Schuster E, Orlowska D, Chont M, Gupta RK, Buvanendran AThe journal of painEndogenous Opioid Function and Responses to Morphine: The Moderating Effects of Anger Expressiveness. J Pain. 2017 08; 18(8):923-932.J Pain2017-03-30T00:00:002017Endogenous Opioid Function and Responses to Morphine: The Moderating Effects of Anger Expressiveness.true1Assistant ProfessorAssistant Professor28642209Cook RL, Weber KM, Mai D, Thoma K, Hu X, Brumback B, Karki M, Bryant K, Rathore M, Young M, Cohen MContemporary clinical trialsAcceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results. Contemp Clin Trials. 2017 09; 60:72-77.Contemp Clin Trials2017-06-19T00:00:002017Acceptability and feasibility of a randomized clinical trial of oral naltrexone vs. placebo for women living with HIV infection: Study design challenges and pilot study results.37469041Ghosh A, Mahintamani T, Kathiravan S, Swer SB, Basu D, Mattoo SK, B N S, Singh ASubstance use & misuseDoes Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India. Subst Use Misuse. 2023; 58(12):1620-1624.Subst Use Misuse2023-07-19T00:00:002023Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India.